Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Receivables (2018 - 2022)

Summit Therapeutics' Receivables history spans 5 years, with the latest figure at $349000.0 for Q4 2022.

  • For Q4 2022, Receivables fell 82.88% year-over-year to $349000.0; the TTM value through Dec 2022 reached $349000.0, down 82.88%, while the annual FY2022 figure was $349000.0, 82.88% down from the prior year.
  • Receivables reached $349000.0 in Q4 2022 per SMMT's latest filing, up from $140000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $22.2 million in Q1 2019 to a low of $140000.0 in Q3 2022.
  • Average Receivables over 5 years is $5.2 million, with a median of $1.4 million recorded in 2022.
  • Peak YoY movement for Receivables: plummeted 97.15% in 2020, then skyrocketed 515.71% in 2021.
  • A 5-year view of Receivables shows it stood at $19.8 million in 2018, then plummeted by 41.4% to $11.6 million in 2019, then tumbled by 97.15% to $331000.0 in 2020, then surged by 515.71% to $2.0 million in 2021, then crashed by 82.88% to $349000.0 in 2022.
  • Per Business Quant, the three most recent readings for SMMT's Receivables are $349000.0 (Q4 2022), $140000.0 (Q3 2022), and $1.3 million (Q2 2022).